Diagnosis and management of asthma – Statement on the 2015 GINA Guidelines by unknown
original article
Wien Klin Wochenschr (2016) 128:541–554
DOI 10.1007/s00508-016-1019-4
Diagnosis andmanagement of asthma – Statement on the
2015 GINAGuidelines
Fritz Horak · Daniel Doberer · Ernst Eber · Elisabeth Horak · Wolfgang Pohl · Josef Riedler · Zsolt Szépfalusi ·
Felix Wantke · Angela Zacharasiewicz · Michael Studnicka
Received: 28 April 2016 / Accepted: 12 May 2016 / Published online: 1 July 2016
© The Author(s) 2016. This article is available at SpringerLink with Open Access
Summary This statement was written by a group
of pulmonologists and pediatric pulmonologists be-
longing to the corresponding professional associa-
tions ÖGP (Austrian Society for Pulmonology) and
ÖGKJ (Austrian Society for pediatric and adolescent
medicine) to provide a concise overview of the latest
updates in the 2015 GINA Guidelines and to include
aspects that are specific to Austria.
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Asthma is one of the world’s most common chronic
diseases and also represents an important cost fac-
tor for health-care systems. The Global Initiative for
Asthma (GINA) has published updated guidelines for
the diagnosis and therapy of asthma in children and
adults annually for over 10 years [4]. This rather vo-
luminous document (>100 pages) in English can be
difficult to implement for practicing physicians and
in part also has to be adapted to local conditions.
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This statement was written by a group of pulmo-
nologists and pediatric pulmonologists belonging to
the corresponding professional associations ÖGP and
ÖGKJ to provide a concise overview of the latest upda-
tes in the 2015 GINAGuidelines and to include aspects
that are specific to Austria. For further details, please
refer to the individual relevant sections of the GINA




Asthma is a heterogeneous,multifactorial disease with
variable andmostly reversible respiratory pathway ob-
struction based on a chronic bronchial inflammato-
ry reaction. The symptoms (cough, rhonchus, wheez-
ing, chest tightness, or shortness of breath) are var-
iable and correlated with expiratory flow limitation.
Although bronchial hyperresponsiveness (BHR) is of-
ten present, the current GINA Guidelines no longer
include it as a necessary or sufficient criterion for di-
agnosis.
Phenotypes
Owing to the heterogeneity of the disease, a number
of different phenotypes can be described. Distinguis-
hing between them can be particularly relevant to the
therapy in severe cases:
● Allergic asthma
● Nonallergic asthma
● Pediatric asthma/recurrent obstructive bronchitis
● Late-onset asthma
● Asthma with fixed airflow obstruction
● Obesity asthma
● Occupational asthma
● Asthma in the elderly
● Severe asthma
Classifications by other professional associations
(ERS/ATS, European Respiratory Society/American
Thoracic Society) tend to focus more on a com-
bination of clinical and pathophysiological aspects
(e. g., eosinophilic/neutrophilic asthma, severe aller-
gic asthma etc.).
Initial diagnosis
Diagnostic criteria and supplementary examinations
Asthma may be suspected if the patient has a positive
medical history of recurrent dry coughing, especial-
ly at night, rhonchus, wheezing, chest tightness, or
shortness of breath.
Lung function testing can confirm the diagnosis if
an airway obstruction is found reversible based on an
FEV1 (Forced expiratory Volume in 1 second) increa-
se of >12% and >200 ml (in adults) after administe-
ring 200–400 µg salbutamol. If there is clinical suspici-
on, but the lung function is normal, further bronchial
challenge testing (e. g., with methacholine or indirect
tests such as running exertion or inhalation of hype-
rosmolar solutions) may be helpful, especially to de-
termine bronchial hyperresponsiveness in adults. Fur-
thermore, an FEV1 increase of +12% and >200 ml (in
adults) after 4 weeks of anti-inflammatory therapy is
considered diagnostic confirmation.
If an allergic trigger is suspected, an allergy diag-
nosis consisting of medical history, skin prick test,
and/or definition of the specific IgE (Immunoglobu-
line group E) should be performed. This should also
include sensitizations that are not clinically relevant
because they can provide prognostic information.
Measuring fractional exhaled nitric oxide (FeNO)
has not yet become an established practice in gener-
al asthma management and is not recommended in
the current guidelines for a general therapy decision
[6]. Nevertheless, in the view of this statement’s au-
thors, there are several indications in which an Fe-
NO measurement makes sense, such as, for exam-
ple: (1) as another component of asthma diagnosis in
difficult cases (normal lung function, unclear symp-
toms), (2) to check on therapeutic adherence regar-
ding inhaled corticosteroid (ICS), or (3) for the early
detection of worsening asthma.
Differential diagnosis
The differential diagnosis for asthma in adults over
40 years of age should primarily consider chronic ob-
structive pulmonary disease (COPD chronic obstructi-
ve pulmonary disease), sinusitis, or gastroesophageal
reflux disease (GERD). The distinction between asth-
ma and COPD can be difficult since symptoms may
overlap, change, or exist in parallel (ACOS Asthma-
COPD overlap syndrome). In younger patients, acute
infections, congenital malformations (respiratory or
heart), or foreign body aspirations may be more pro-
minent (Table 1).
Follow-up
Asthma follow-up: symptoms and minimization of
future risks
Asthma therapy aims to achieve maximum freedom
from symptoms (nocturnal awakening, need for res-
cue medication, activity restrictions) and, thereby,
maximum quality of life (Table 2). This can in most
cases be achieved with consistent therapy. Therapeu-
tic adherence is a problem because patients often do
not suffer in spite of poor lung function and disconti-
nue their therapy without asking their physician once
they have experienced a quick response. Regular lung
function controls are necessary, and a questionnaire
such as the Asthma Control Test (ACT) can provide
additional help for evaluating therapeutic efficacy in
relation to symptom control.
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Table 1 Commondifferential diagnoses for asthma
≤5 years 6–11 years 12–39 years 40+ years
Recurrent viral infections X
Gastroesophageal reflux X
Congenital malformations (tracheomalacia, vascular ring etc.) X
Tuberculosis X




Foreign body aspiration X X X
Congenital heart defects X X X
Cystic fibrosis X X X
Chronic cough (upper respiratory tract) X X
Bronchiectasis X X X
VCD X X
Hyperventilation X X
Alpha1-antitrypsin deficiency X X
COPD X
Left ventricular heart failure X
Drug-related cough X
Parenchymatous lung disease X
Pulmonary embolism X
Central airway obstruction X
According to GINA update 2015, modified by the author team
PCD primary ciliary dyskinesia, BPD bronchopulmonary dysplasia, VCD vocal cord dysfunction, COPD chronic obstructive pulmonary disease
Table 2 Asthmacontrol according toGINA for adults and
children


















due to asthma (or
coughinga) at any time
Reliever >2×/week (or
>1×/weeka)
Any limitation of daily
activity due to asthma
aIn children ≤5 years
Risk minimization includes smoking cessation, op-
timal protection from contaminants in the workplace,
and specific immunotherapy.
Lung function control
A lung function test should be performed for diagno-
sis or prior to starting therapy. Follow-up should oc-
cur individually based on asthma severity/symptoms
in intervals of 3–6 months. In addition to these rec-
ommendations of the GINA Guidelines, lung functi-
on testing, performed approximately 4–6 weeks after
a change of therapy, has proven successful for control-
ling treatment efficacy. A minimally relevant change in
the FEV1 is indicated as 10%.
Spirometry can generally be performed in children
from about 6 years of age. Prior to that, diagnosis and
follow-up have to rely on clinical parameters (see “Pre-
schoolers”). It is important to note that spirometry re-
sults tend to be normal in many children with asthma
and only show FEV1 restrictions during exacerbations.
Determination of asthma severity
The classification of asthma severity has fundamen-
tally changed over the past years. Traditionally, the
degree of severity (intermittent, mild, persistent etc.)
was based on symptoms and the use of rescue inha-
lers and limited lung function. Strictly speaking, this
classification only applied to untreated patients. Since
the response to treatment is essential, GINA has re-
commended the concept of asthma control and ther-
apy steps since 2006. Severity therefore is no longer
a snapshot, but is established retrospectively after a
treatment period of several months and can change
over time. It results from the therapy step that is re-
quired to achieve asthma control (see Table 2):
● Mild asthma: therapy step 1 or 2
● Moderate asthma: therapy step 3
● Severe asthma: therapy step 4 or 5
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Fig. 1 Investigationof apatientwithpoor symptomcontrol or
exacerbationsdespite therapy
In addition, the concept of severe asthma was clearly
defined and differentiated from other terms such as
uncontrolled or “difficult-to-treat” asthma. An exact
definition can be found in a separate ERS/ATS guide-
line from 2014, to which GINA also makes reference
[3]. “Severe asthma” is reserved for patients with ac-
tual therapy-resistant asthma after other factors such
as poor inhalation technique and adherence to ther-
apy, risk factors, continuous exposure to trigger factors
(e. g., allergens, smoke) or co-morbidities have been
excluded or optimally treated and the patient has re-
ceived treatment from an asthma specialist for at least
3 months (see Fig. 1).
The World Health Organization term “untreated se-
vere asthma” (common in countries with inadequate
treatment options) also is no longer included in this
definition of severe asthma.
It should also be noted that therapy steps 4 and 5
according to GINA or ERS/ATS have significant diffe-
rences based on the defined limit values for high-dose
ICS therapy (doses according to ERS/ATS are in part
double compared with GINA). This has an indirect ef-
fect on the definition of severe asthma.
Therapy and management
Goals
General long-term objectives of asthma management
include:
● Achieving symptom control and maintaining nor-
mal physical performance
● Minimizing the risk of exacerbations, fixed airway
obstruction, and side effects of the therapy
Fig. 2 Cycleof asthmacontrol
Furthermore, individual goals should be discussed
with the patient and taken into account. A good part-
nership between the patient and the physician is es-
sential for effective asthma management. Physicians
should have good communication skills to encourage
patients to take part in decisions and to express their
needs and concerns. Patient self-management and
knowledge about asthma should be promoted with
training, as studies have documented positive effects
on morbidity in adults and children.
Control-based asthma management
Modern asthma treatment (pharmacological and non-
pharmacological therapy) is based on the concept of
asthma control, which has been shown to improve the
treatment success. This concept is based on a cycle of
assess, adjust, and review (see Fig. 2).
Symptom control is usually associated with redu-
ced asthma exacerbations. In the case of more severe
forms, symptom control can occasionally not be pai-
red with a reduced exacerbation rate. That makes it
important to consider both factors of asthma control
(symptoms and exacerbation risk).
As an alternative, other concepts such as therapy
based on sputum or FeNO may be used in special
cases, e. g., severe or difficult-to-treat asthma.
Drug therapy
Inhalation therapy is the application of choice for
asthma. It leads to higher local concentrations, fewer
systemic side effects, and, accordingly, to generally
very good tolerance compared with systemic appli-
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Table 3 Medicationcategories for asthma treatment
Controller Reliever Add-on therapya
Inhaled corticosteroid (ICS)
ICS/LABA (long-acting beta-2-agonist) combination
Leukotriene receptor agonists (LTRA)
Long-acting anticholinergics (LAMA)
Methylxanthines (theophylline)






Special (phenotype-specific) treatments and interven-
tions by specialized centers
aAdd-on therapies should be prescribed by specialized physicians with experience in asthma management
Table 4 Controller therapyafter initial diagnosis
Presentation Recommended initial therapyc
– Symptoms or need for SABA <2×x/month
– No nocturnal awakening
– No risk factorsa for exacerbation
– No exacerbation in the last 12 months
No controller
– Symptoms or need for SABA <2×/month
– No nocturnal awakening
– At least one risk factora for exacerbation or one exacerbation (with OCS therapy) in the last
12 months
Low-dose ICS
– Symptoms or need for SABA ≥2×/month
– Nocturnal awakening ≥1×/month
Low-dose ICS
– Symptoms or need for SABA >2×/month Low-dose ICS
– Symptoms on most days
– Nocturnal awakening ≥1×/month




bNot recommended as initial therapy for children up to age 11 years
cSABA used on demand in all cases
cation. Three pharmaceutical categories are generally
distinguished for long-term treatment (Table 3):
● Controller: Taken regularly. Reduces inflammation
and exacerbation risk and controls symptoms.
● Reliever: Taken as necessary to reduce symptoms
in case of asthma exacerbations. Also used for the
short-term prevention of exercise-induced bron-
choconstriction. It is a key objective of asthmaman-
agement to keep the need for reliever to aminimum.
● Add-on: Used in patients with severe asthma and
persistent symptoms or exacerbations despite high-
dose combination therapy with ICS and optimizati-
on of modifiable risk factors.
Initial treatment after diagnosis
To achieve the best possible results, a maintenance
therapy with a controller should be initiated as quick-
ly as possible after the diagnosis of asthma (improves
lung function or reduces deterioration of lung func-
tion after an exacerbation; see Table 4). Since GINA
2014, a low-dose ICS therapy has been listed as an
option for older children and adults at step 1 for spe-
cific symptom and risk constellations. For preschool
children with intermittent symptoms, the initial ther-
apy consists of an inhaled short-acting beta-2-agonist
(SABA). Further therapeutic steps are based on the
degree of asthma control.
Stepwise approach for adjusting asthma treatment
The adjustment of asthma therapy is based on asthma
control, and follows a step-up/step-down algorithm
to increase or reduce the medication (Fig. 3). Regu-
lar follow-up should occur in a period of 2–3 months
to optimize the treatment strategy. It is important to
record symptom control, lung function, risk factors,
inhalation technique, adherence, and nonpharmaco-
logical strategies on a regular basis.
The gold standard in asthma therapy is still a low-
dose ICS as a controller together with an on-demand
Short-acting beta-2-agonist (SABA). An LTRA (Leuco-
triene-receptor antagonist) can be tried as a second
choice. There are also considerations that a combina-
tion product with low-dose ICS and long-acting beta-
2-agonist (LABA) should be established in adults at
this treatment stage (step 2) to ensure rapid treatment
success. A further step-up from step 3 for adults calls
for ICS–LABA combination therapy, with ICS in low
doses. For children over the age of 12 years, an incre-
ased ICS dose is preferred over a combination therapy
in this case. Two inhalers are also approved for ad-
ditional rescue therapy: Formoterol/budesonide and
formoterol/beclomethasone as basic therapy should
be administered in the morning and at night and may
also be inhaled by patients as needed (exacerbation).
The ICS concentration in the combination product
increases with the severity of the disease. Tiotropium
may now be added to the management regimen as an
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Fig. 3 Stepalgorithmof asthma therapy for adults andchildrenolder than5years
additional treatment option. The use of theophylline
preparations is still defined in the guidelines, but they
are rarely employed in practical situations. A further
innovation in the step-up algorithm is the applicati-
on of an add-on therapy (e. g., anti-IgE for patients
with severe asthma, who show a corresponding aller-
gic predisposition prior to a systemic steroid therapy.
In the same way as the step-algorithm provides
for step-up options, it is important to reduce (step
down) the therapy after the corresponding controls
(after approximately 2–3 months) with good asthma
control. Again, this requires a highly sensitive ap-
proach to quickly detect deteriorating symptoms and
lung function, which may indicate an elevated risk
of exacerbations. In principle, the goal should be to
use the lowest ICS concentration that can guarantee
optimal therapeutic success.
Asthma therapy for preschoolers basically has the
same objectives as approaches for older children and
adults and also follows a step scheme (step-up or step-
down). In this age group, minimization of pharmaceu-
tical side effects (e. g., body growth limitations from
use of ICS) is especially important (see “Preschoo-
lers”).
Choice of inhaler
For children and adults, the choice of inhalers is ba-
sed on individual skills (e. g., inspiratory flow) or bar-
riers (e. g., arthritis, muscle weakness, impaired visi-
on). Until early school age, most patients should use
an inhaler with a suitable spacer. Oral/nasal masks
should only be applied if the use of a mouthpiece is
not possible (for reasons of age or compliance). In the
age group of about 8 years and older, most patients
use dry powder inhalers (DPI). If possible, patients
should be involved in the choice of inhalers. Since
there is no perfect tool, regular checks as well as trai-
ning are necessary for the effective use of inhalers. The
use of several different inhalers should be avoided to
prevent confusion.
Steroid dosage
The bulk of ICS effects can be achieved with low do-
ses; few studies are available on dose–response rela-
tionships for conventional doses. Low daily doses are
not associated with clinically relevant adverse effects,
but high doses pose a larger risk of systemic side ef-
fects with prolonged application (although this risk is
smaller than with systemic application). ICS should
be titrated to find the minimum effective dose that
achieves good symptom control and a minimal risk of
exacerbation. The dose ranges for each age group are
listed in Table 5.
Specific immunotherapy
Although the GINA Guidelines are cautious in their
recommendation of specific immunotherapy (SIT), an
increasing volume of study data justifies its use in pa-
tients with mild-to-moderate, controlled allergic asth-
ma [1]. It is important in each case that the allergen
is a relevant asthma trigger (e. g., grass or birch pollen
seasonally or house-dust mites as perennial allergens)
and that the asthma is controlled (see Table 2). Partic-
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Table 5 Dailydoseequivalentsof inhaledcorticosteroids
Drug Daily dose (mcg)
Low Medium Higha
Adolescents and adults
Beclomethasone dipropionate (CFC) 200–500 >500–1,000 >1,000
Beclomethasone dipropionate (CFC) 100–200 >200–400 >400
Budesonide (DPI) 200–400 >400–800 >800
Ciclesonide (HFA) 80–160 >160–320 >320
Fluticasone propionate (DPI) 100–250 >250–500 >500
Fluticasone propionate (HFA) 100–250 >250–500 >500
Mometasone furoate 110–220 >220–440 >440
Triamcinolone acetonide 400–1,000 >1,000–2,000 >2,000
School children
Beclomethasone dipropionate (CFC) 100–200 >200–400 >400
Beclomethasone dipropionate (CFC) 50–100 >100–200 >200
Budesonide (DPI) 100–200 >200–400 >400
Budesonide (nebulizer) 250–500 >500–1,000 >1,000
Ciclesonide 80 >80–160 >160
Fluticasone propionate (DPI) 100–200 >200–400 >400
Fluticasone propionate (HFA) 100–200 >200–500 >500
Mometasone furoate 110 ≥220–<440 ≥440
Triamcinolone acetonide 400–800 >800–1,200 >1,200
Preschoolers
Beclomethasone dipropionate (HFA) 100
Budesonide (DA + spacer) 200
Budesonide (nebulizer) 500
Fluticasone propionate (HFA) 100
Ciclesonide 160
CFC chlorofluorocarbon as propellant, MDI metered-dose inhaler; DPI dry powder inhaler, HFA hydrofluoroalkane as propellant
aThe guidelines of ATS/ERS on severe asthma use significantly higher cut-offs than specified here
ularly in the case of additional rhinoconjunctivitis, SIT
can be taken into consideration for children from the
age of 6 years with controlled asthma. Proper aller-
gy diagnosis and the use of standardized vaccines are
prerequisites for successful immunotherapy.
The treatment of asthma patients with specific im-
munotherapy should only be performed by doctors
who are familiar with asthma management. Meticu-
lous asthma control is required, especially in the step-
up phase, for the problem-free performance of a spe-
cific immunotherapy.
Subcutaneous immunotherapy (SCIT) is still the
gold standard for treatment. However, a significant
reduction of steroid use and exacerbations was re-
cently demonstrated with the use of a sublingual
high-dose house-dust mite tablet in asthma patients
[5].
Nonpharmacological therapy
This section particularly refers to those patients who
continue to suffer from asthma exacerbations in spi-
te of presumably optimal or even maximum phar-
macological therapy (see also “difficult-to-treat asth-
ma”). However, many of the points listed, especially
the avoidable factors (e. g., smoking, inactivity) are of
relevance for all other asthma patients as well.
The identification of modifiable factors frequent-
ly leads to ultimate success. GINA discusses the fac-
tors to be considered and lists the corresponding le-
verage points. The detection of risk factors in the li-
ving environment of the patient and the implementa-
tion of improvement measures require a time-inten-
sive doctor–patient dialog as well as the patient’s wil-
lingness to actively cooperate. Ultimately, successful
asthma therapy is based on the complex interaction
between doctor, patient, therapy, and the patient’s en-
vironment.
The main modifiable factors listed in GINA are
briefly summarized in Fig. 4.
Comorbidities
A number of health conditions can influence the cour-
se of asthma, thereby severely limiting asthma control
and negatively affecting the patient’s life quality.
The presence of an inflammatory disease in the up-
per airways (rhinitis, rhinosinusitis) increases the risk
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Fig. 4 Uncontrolledasthma–additional therapeuticmeasuresandmodifiable factors
of developing asthma. In all, 10–40% of patients with
allergic rhinitis have asthma, suffer from more fre-
quent exacerbations, and also need more rescue me-
dication. Treating rhinopathy in patients with existing
asthma is an important part of the therapy.
The heterogeneity of asthma can in part also be
explained by the clinical characteristics of the comor-
bidities. This also includes obesity asthma, which ge-
nerally represents a therapeutic challenge. Additional
factors such as obstructive sleep apnea, GERD and
small lung volumes complicate management of this
special type of asthma, which has been intensively
researched over the past few years. Common therapy
concepts such as ICS are not successful, while a weight
loss of 5–10% leads to a significant improvement of
asthma control and life quality.
GERD is a trigger frequently found in adults, which
is not only associated with increased cough episodes,
but can also trigger asthma attacks. Asthma medicati-
ons such as beta-2-agonists and theophylline prepa-
rations can aggravate these symptoms. In the case of
uncontrolled asthma, it is generally recommended to
look for GERD and to prescribe an empirical anti-re-
flux therapy for at least 6 weeks if GERD is suspected.
In some cases, an endoscopic investigation or a 24-h
pH measurement is required. The treatment consists
of a high-dose PPI (protone-pump inhibitor) medica-
tion. Surgical procedures (fundoplication) in patients
with therapy-resistant asthma must be considered as
a final resort.
Psychological disorders are generally underestima-
ted in asthma patients and often are associated with
a low therapy adherence. Accordingly, these patients
frequently experience exacerbations and have to seek
emergency room treatment. Anxiety and depressive
disorders should be professionally investigated, and
patients should be trained to prepare for emergen-
cies. Optimal pharmacological treatment is the basis
for a better outcome in these patients.
In rare cases, food allergies are the triggers of asth-
ma symptoms. Serious, even fatal reactions have been
reported for patients with documented food-induced
allergic reactions (anaphylaxis) and asthma. Because
such patients frequently are allergic to peanuts or tree
nuts, patients with food allergies should always be ex-
amined for the possible presence of asthma. Special
allergological examinations can provide key informa-
tion for the further management of these patients. In
order to minimize the risk of an anaphylactic reaction,
patients should receive a prescription for an adrena-
line auto-injector and be instructed in its use.
Disorders in specific populations
Adolescents
This section makes specific reference to the develop-
mental changes occurring primarily in this age group
(social, emotional, physical etc.). A range of different
behavioral tendencies (such as smoking) must be ta-
ken into account. It is recommended to create an in-
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dividual schedule that reflects the teen’s life situation
and daily routine (topic: inhalation therapy – when
and how often?).
Exercise-induced bronchoconstriction
Physical activities are an important trigger for the oc-
currence of asthma symptoms, although bronchocon-
striction and the associated symptoms typically occur
after exertion. Shortness of breath during exercise is
more closely associated with a lack of physical fitness,
obesity, or other illnesses. A well-founded pharmaco-
logical therapy can lead to significant improvements
in exertion capacity, in which the administration of
SABA can be sufficient to achieve substantial con-
trol. In some cases, regular treatment with ICS or ICS/
LABA is required. Therapy with LTRA has also pro-
ven successful with this form of asthma. Targeted trai-
ning measures and sufficient warm-up are important
aspects of therapy.
Asthma in pregnancy
To avoid asthma exacerbations during pregnancy, pa-
tients should continue their treatment according to
the GINA Guidelines. Therapeutic adherence can be
problematic because pregnant women find it less ac-
ceptable to use ICS. If the asthma is well controlled
during pregnancy, the risk of complications for mo-
ther or child is low. The use of ICS, SABA, and LTRA
is not associated with an increased incidence rate of
fetal abnormalities. The principle of avoiding asthma
exacerbations with optimal therapy is particularly im-
portant during pregnancy. Continued ICS therapy sta-
bilizes the asthma, while a discontinuation elevates
the risk of clinical deterioration.
Asthma training and self-management
GINA has a very clear position on the purpose of struc-
tured asthma training and nonpharmacological asth-
ma management. The main content should be deve-
loped jointly and mainly concerns information on ac-
tions to take, training in self-management with recor-
ding of symptoms and possibly measurement of peak
flow, the preparation of a written action plan, and re-
gular follow-up for asthma control.
Training particularly focuses on the effective hand-
ling of the inhalation devices. Necessary steps include
the selection of the most suitable inhaler for a specific
age, reviewing inhalation technique, and demonstra-
tions of correct application by the trainer. The patient
should confirm the learning outcome by demonstra-
ting the inhalation.
Therapeutic adherence should be checked at each
visit, with recording of the possible causes of poor
adherence. Around 50% of all adults and children
using long-term asthma therapy do not properly com-
ply with their treatment regimen. How can adherence
be verified? The guidelines make a few suggestions,
which are generally based on “empathy” questions
that are not moralizing or patronizing. The guidelines
again emphasize the importance of shared decisions
for an individually implementable therapy.
Information is part of every asthma training. It
should be relevant for action and individually adap-
ted to the development level of children. Training for
preschoolers should be interactive, creative, and play-
ful. It should be noted that information alone does
not improve the outcome and should therefore only
be part of a training that includes effective and prac-
tical aspects. It is recommended to address personal
expectations, concerns, and fears so as to develop
shared goals.
The communication of a self-management con-
cept must reflect the personal situation of the family.
Symptoms can be logged with a diary or an appro-
priate app. Given the low sensitivity and specificity
of this method, peak flow measurement only makes
sense in children who have severe or difficult-to-treat
asthma.
The written asthma action plan that forms part of
self-management should contain clear recommenda-
tions for the use of bronchodilation and anti-inflam-
matory therapy in acute and long-term management.
In addition, it should be specified in detail how and
when to seek medical assistance.
The benefits of telemedicine are seen as rather limi-
ted and should be primarily restricted to patients with
severe forms of the disease. Regular medical consulta-
tion is regarded essential to implement the necessary
aspects of pharmacological-based and nonpharmaco-
logical-based asthma management.
Table 6 Risk factors for asthmaexacerbationsor asthma-
relateddeaths
Increased risk of asthma exacer-
bations
Increased risk of death
Uncontrolled asthma symptoms
High SABA usea
Use (currently or until recently) of OCS
Inadequate ICS use (not pres-
cribed, wrongly inhaled, poor
adherence)
No ICS inhalations; poor adherence to
prescribed asthma medications, no
asthma action plan (or not followed)
Low FEV1 (especially <60%
predicted)
Serious psychosocial problems
Exposed to: smoking, allergens (in
case of existing allergy)
Existing food allergy
Sputum or blood eosinophilia
Pregnancy
Previously intubated or in an
intensive care unit for asthma
Near-lethal episode with intubation
and ventilation
≥1 serious exacerbations in the
last 12 months
Hospitalization or presentation in the
emergency room due to asthma in the
last year
aIncreased risk of death with >1 package of a salbutamol (or similar) MDI
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Table 7 Modificationofmedication in thecaseof asthmaexacerbation
Existing medication Modification (for 1–2 weeks)
Reliever (or C&R):
– SABA
– Low-dose ICS/formoterol (C&R)
Increase reliever:
– Increase SABA frequency
– Increase reliever use (up to 72 µg/day formoterol)
Controller:
– ICS/formoterol (C&R)a
– ICS + SABA
– ICS/formoterol (C) + SABA
– ICS/salmeterol + SABA
Increase controller:
– Increase ICS/formoterol use (up to 72 µg/day formoterol)
– Double ICS dose/increase to high-dose therapy step
– Quadruple ICS/formoterol use (up to 72 µg/day formoterol)
– Increase to high-dose ICS/salmeterol or ICS separately
Any therapy Add OCS and seek medical assistance:
– OCS for severe exacerbations (for criteria, see above)
– Adults: 5–7 days 1 mg/kg/d prednisolone (max. 50 mg)
– Children: 3–5 days 1–2 mg/kg/day prednisolone (max. 40 mg)
– No wash-out phase required if administered <2 weeks
– Double ICS dose/increase to high-dose therapy step
– Quadruple ICS/formoterol use (up to 72 µg/day formoterol)
– Increase to high-dose ICS/salmeterol or ICS separately
C as controller, R as reliever
aNot approved for children under 12 years of age
Management of asthma exacerbations
An asthma exacerbation is an episode with increasing
shortness of breath, cough, and wheezing involving
restricted lung function. It is commonly caused by
known triggers (respiratory infection, pollen, air pol-
lution). This deterioration can be described in diffe-
rent terms, such as exacerbation, episode, acute seve-
re asthma, or “flare-up.” In addition to the aforemen-
tioned trigger factors of an asthma exacerbation, they
also – occasionally at the same time – represent key
risk factors for asthma-related death (Table 6).
Diagnosis of exacerbations
An exacerbation is defined as a deterioration of lung
function (FEV1) and/or the occurrence or deteriorati-
on of respiratory symptoms. While lung function con-
stitutes an objective indicator, especially for deter-
mining the severity of the exacerbation, the frequen-
cy of respiratory symptoms is often a more sensitive
parameter. Particular attention must be paid to pa-
tients who are less skilled at noticing or articulating
their symptoms (children, male patients, patients with
a near-lethal asthma event in the past).
Themanagement of an asthma exacerbation occurs
in stages and depends on the severity or the course.
In principle, three stages can be distinguished:
● At home (self-management)
● At the family physician
● In the hospital/emergency room
Self-management (at home)
All asthma patients should be trained in self-manage-
ment and receive a written asthma action plan, which
defines individual criteria for the modification of the
controller therapy and typically pertains to symptoms
and a drop in the PEF (Peak Expiratory Flow) (e. g.,
>20% for more than 2 days). A general scheme is
shown in Table 7 and Fig. 5.
Patients should be examined by a physician within
1–2 weeks of an exacerbation. In general, the control-
ler therapy can be reduced to the original step after
2–4 weeks.
Management by a general practitioner or pediatrician
In the medical setting, the following points need to be
considered in the case of an exacerbation:
● Brief medical history and physical examination
● Assessment of exacerbation severity
● Prompt initiation of therapy
Medical history should include:
● Time and cause of exacerbation
● Severity of symptoms (physical performance and
sleep)
● Signs of anaphylaxis
● Risk factors for asthma-related death (Table 6)
● Medication (reliever and controller, adherence, and
recent changes)
Clinical examination should include:
● Vital signs and signs of severity (see Fig. 6)
● Signs of complications (e. g., anaphylaxis, pneumo-
nia, pneumothorax)
● Signs of alternative diagnoses (e. g., foreign body,
pulmonary embolism, heart failure, dysfunction of
the upper respiratory tract)
Antibiotic therapy plays no role in asthma exacerba-
tions, unless there is clear evidence of a pulmonary
infection (e. g., fever, purulent sputum, or radiologi-
cally documented infiltration).
Management in the emergency room/hospital
Severe asthma exacerbations are life-threatening me-
dical emergencies. Some 50–100 people still die of
asthma in Austria every year (Austrian Statistics). It
is usually safest to handle such emergencies in hospi-
tal emergency rooms (Fig. 7). This overview does not
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Fig. 5 Self-management in
caseof exacerbations
Fig. 6 Severity signsof an
asthmaexacerbation
include any details on intensive-care management of
asthma.
Analogous to the management provided by a gener-
al practitioner and/or pediatrician, the challenge is to
quickly perform the three components (medical his-
tory and physical examination, assessment of sever-
ity, and prompt initiation of therapy). PEF and oxy-
gen saturation measurement can be supplemented
with a spirometry, arterial blood gas analysis and, if
necessary, a chest X-ray.
Therapies not recommended for acute care include
intravenous methylxanthine (poor risk–benefit profi-
le), helium oxygen therapy (exceptional cases only),
LTRA, antibiotics, and sedatives (increased mortality).
The use of noninvasive ventilation (NIV) is controver-
sial, particularly for agitated patients. Under no cir-
cumstances should the patient be sedated to allow for
NIV.
The postdischarge therapy follows the same guide-
lines as for management by a general practitioner or
pediatrician. Patients should be promptly and repea-
tedly evaluated by the physician providing treatment
in the weeks following the exacerbation.






Asthma is a heterogeneous disease and ultimately the
result of a gene–environment interaction. According
to general consensus, there is a “window of opportu-
nity” during pregnancy and early childhood, in which
environmental factors can modify the development
of asthma. GINA briefly addresses the most compre-
hensively studied factors, including breastfeeding, vi-
tamin D, supplementary food, probiotics, inhaled all-
ergens, tobacco smoke, microbial effects, drugs (anti-
biotics, paracetamol), as well as psychological aspects.
At the end of the chapter, GINA provides a recom-
mendation for generally applicable advice to parents
regarding primary asthma prevention:
● Avoid exposure to second-hand smoke, especially
during pregnancy and in the child’s first year of life.
● Seek vaginal birth if possible.
● Breastfeed (generally positive health effects).
● Only use broad-spectrum antibiotics during preg-
nancy and in the child’s first year of life if absolutely
necessary.
For the other aforementioned factors, there are eit-
her insufficient data (or partly controversial) to give
a general recommendation or the approaches are not
generally applicable to everyone (e. g., growing up on
a farm).
Preschoolers
For the age group 0–5 years, there are significant dif-
ferences in the entire asthma management from diag-
nosis to therapy [2]. Therefore this group is discussed
in a separate section of the GINA Guidelines.
Diagnosis
The possibility of a first manifestation in infants or
toddlers makes diagnostic determination difficult in
this age group because congenital disorders and a wi-
de range of differential diagnostic possibilities (see Ta-
ble 1) have to be taken into account and may need to
be investigated along with perinatal aspects.
A special feature in this age group is that many
children suffer from asthma-like symptoms, while the
number of children who are completely symptom-free
in later life is very high. Children under 3 years of age
commonly exhibit wheezing within the context of viral
infections, and every third child suffers from episodic
symptoms, frequently with excellent long-term prog-
nosis. There are no reliable tests to distinguish be-
tween transient symptoms and true early childhood
asthma – with the associated need for therapy.
The most significant indicators of early childhood
asthma include:
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● Typical symptoms such as wheezing and coughing
without an infection, also frequently during exerti-
on/laughing/crying as well as reduced activity level
and particularly nocturnal symptoms
● Risk factors for asthma (especially positive family
history of allergies or asthma)
● Response to a therapy attempt with low-dose ICS
and SABA on demand for 2–3months
The following additional examinations may be consi-
dered:
● Allergy test: Reasonable because many children
show relevant sensitization even under 3 years of
age. For example, sensitivity to house-dust mites is
associated with increased asthma risk.
● Lung function diagnostics: Children usually have to
be 5–6 years old before spirometry is possible, but
it can be attempted earlier with sufficient experti-
se and time investment. The GINA Guidelines do
not make any reference to alternative technologies
(forced oscillation, impulse oscillometry, multiple-
breath washout etc.). In addition, these techniques
currently are only available in specialized centers.
● Exhaled NO: Listed as a possible examination (ti-
dal technique) in the GINA Guidelines, but not yet
established for young children (apart from scienti-
fic applications). As soon as spirometry is possible,
the forced expiratory flow maneuver can usually be
employed in a defined flow range (“single-breath”
method).
● Further tests, mainly to rule out differential diagno-
ses: In addition to the lung X-ray specified in the
GINA Guidelines, further examinations (bronchos-
copy, sweat test, pH measurement etc.) may be re-
quired. However, they are not part of the primary di-
agnosis.
Therapy and management
Asthma control plays an important role, as in older
children and adults. The GINA Guidelines offer a ta-
ble on asthma control, which is similar to the table for
older children and adults (see Table 2). It distinguis-
Fig. 8 Stepalgorithmof
asthma therapy for children
≤5years
hes between well-controlled, partly controlled, and
uncontrolled asthma. In the case of young children,
criteria are a little stricter (e. g., daily symptoms or
SABA demand more than once a week compared with
twice a week for older children; nocturnal cough is
listed in addition to nocturnal awakening).
Pharmacological therapy
Pharmacological therapy follows a step algorithm, si-
milar to older children, which is adapted to the age
group (Fig. 8). An inhaled SABA on demand is the first
choice in step 1; this on-demand therapy is recom-
mended for all further therapy steps.
It is further recommended to refer the patient to
a specialist from step 4 (if increasing the daily ICS
dose does not lead to any improvement). Compared
with previous guidelines, the administration of LTRA
has declined in significance and is only recommended
as an option. Current Austrian recommendations [7]
also give preference to a primary therapy with low-
dose ICS over an initial therapy with LTRA, since most
of the children (especially those with allergies) benefit
more from therapy with ICS. The GINAGuidelines also
point out that oral administration of a beta-2-agonist
is not recommended owing to the slower onset and
higher rate of side effects.
The selection of the optimal inhaler for application
of ICS and SABA is equally relevant for preschoolers
because they can only properly inhale when breathing
normally. The choice of inhaler is based on the child’s
age and ability. The preferred device for preschoolers
is a metered-dose inhaler with a spacer and valve. It
should have a mask for children under 4 years of age
and a mouthpiece for most children from 4 years on.
It is important to know that the administered medi-
cation dose may vary considerably among different
spacers. Nebulizers can be used as an alternative for
the few preschool children who cannot inhale effec-
tively in spite of practicing with ametered dose inhaler
with spacer.
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Regular re-evaluation and adjustment of the ther-
apy is particularly important in this age group. Follow-
up should occur within 3 months after every therapy
modification.
Asthma training and asthma plan
Asthma training also makes sense for this age group.
Emphasis should be on basic information about asth-
ma, communicating the right inhalation technique
and presenting a written asthma action plan (see also
“Asthma training and self-management”).
The onset of symptoms, severity, presence of dif-
ferential diagnostic information, considerations con-
cerning the inhalation technique, and, in many cases,
inadequate therapeutic success frequently lead to the
involvement of pediatric experts. This is highly rele-
vant, since development-related aspects must be con-
sidered along with the fact that the absence of symp-
toms must be the objective of the treatment for this
age group as well.
Conclusion
Guidelines contribute to a standardized, uniform ap-
proach for the diagnosis, treatment, and management
of major diseases. The GINA Guidelines have suppor-
ted this effort in the area of asthma management for
many years. New additions to the current guidelines
include a differentiated definition of asthma that ma-
kes specific reference to the heterogeneous symptoms
of the disease and no longer emphasizes bronchial
hyperresponsiveness. The guidelines strongly encou-
rage regular adaptation of the therapy regimen and
the consistent reassessment of patients with different
methods (clinical, lung function etc.). The role of ICS
is highlighted in therapeutic aspects. These pharma-
ceuticals should be used at an early point in the cour-
se of the disease, preferably in low doses. ICS are now
given priority over LTRA in the treatment of young
children. At the highest treatment step, the concept
of add-on therapy is recommended over an OCS ther-
apy for adults. The guidelines again place particular
emphasis on selecting the right inhaler and providing
adequate asthma training. The implementation of the
existing guidelines in routine treatment of asthma pa-
tients will be important for the future. Sufficient re-
sources are necessary to enable training for private
practitioners in hospitals as well as a comprehensive
training program for asthma patients.
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